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Background: Oxidative stress (OS) has been implicated in the development of pulmonary 
hypertension (PH) and ventricular hypertrophy. Xanthine oxidase is a well-recognised source 
of reactive oxygen species, which lead to OS. The aim of this proof of concept study was to 
assess whether allopurinol (xanthine oxidase inhibitor) would reduce right ventricular mass 
(RVM) in patients with PH-associated chronic lung disease (PH-CLD).
Methods: We conducted a randomised, double-blind, parallel-group, placebo-controlled 
trial in patients with PH-CLD (93% COPD, 7% IPF) who were randomly assigned to receive 
allopurinol or placebo for 12 months. The primary outcome was the mean change in RVM, as 
assessed by cardiac magnetic resonance imaging (CMRI). Secondary outcomes included 
quality of life (QOL), spirometry and six-minute walk test (6MWT).
Results: Seventy-one patients were recruited: mean age 71 years, mean pulmonary arter-
ial pressure 30 mm Hg, FEV1 60% and resting SpO2 96%. After 12 months, there was no 
significant difference in the change in RVM from baseline (allopurinol 1.85g vs placebo 
0.97g with mean difference 0.88g, CI −4.77 to 3.01, p =0.7). There were also no significant 
changes in other cardiac parameters measured on MRI, in QOL, spirometry and 6MWT. 
Subgroup analysis showed that allopurinol significantly reduced RVM compared to placebo 
with -6.16g vs 0.75g and mean difference 6.92g (CI 1.14 to 12.69, p = 0.02) in COPD 
patients with more severe airflow limitation.
Conclusion: Allopurinol had no overall impact on patients with PH-CLD but had potential 
benefit in COPD patients with more severe airflow limitation.
Keywords: pulmonary hypertension, right ventricle, allopurinol, chronic lung disease
Introduction
The development of pulmonary hypertension (PH) is a well-recognised complica-
tion of many chronic lung diseases and is generally mild to moderate in severity. 
The most common chronic lung diseases associated with PH are chronic obstructive 
pulmonary disease (COPD) and interstitial lung disease (ILD).1 Irrespective of the 
underlying pulmonary aetiology, the presence of even mild PH is associated with 
deterioration in exercise capacity, worsening of hypoxaemia and shorter survival.2,3
Pulmonary hypertension in hypoxaemic lung diseases is attributed to multiple factors 
including pulmonary vasoconstriction caused by alveolar hypoxia and the distortion of 
pulmonary vessels by parenchymal changes.4 Right ventricular hypertrophy (RVH) is 
believed to be the consequence of chronic pulmonary hypertension.5 RVH is the initiating 
step in the progression to right ventricular (RV) failure in lung disease.
At present, there is no specific therapy recommended for patients with group 3 
PH associated with lung disease.1 The European Respiratory Society advocates 
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optimising the treatment of the underlying lung disease 
and advises that patients should receive long-term oxygen 
therapy (LTOT) if they are hypoxaemic as LTOT has been 
shown to partially reduce the progression of PH in 
COPD.1
Allopurinol is a xanthine oxidase inhibitor which 
decreases both uric acid (UA) and oxidative stress (OS). 
Five experimental studies have shown that allopurinol 
inhibits hypoxia-induced pulmonary vasoconstriction, pul-
monary hypertension, endothelial dysfunction and vascular 
remodelling.6–10 Hypoxia is known from many studies to 
up-regulate xanthine oxidase and therefore to increase its 
production of UA and OS.6 Hypoxia-induced oxidative 
stress has also been shown to have a direct effect in the 
development of ventricular hypertrophy.11 Allopurinol has 
also been shown in clinical studies to reduce left ventri-
cular mass in patients with chronic kidney disease, opti-
mally treated ischaemic heart disease and type 2 diabetes 
mellitus.12–14
The aim of this proof of concept study was to 
investigate whether high-dose allopurinol would 
reduce right ventricular mass in patients with pulmon-
ary hypertension associated with chronic lung disease 
(PH-CLD).
The hypothesis is that allopurinol would reduce the 
production of reactive oxygen species, thereby decreasing 
oxidative stress, which would lead to reduction in right 
ventricular mass in patients with PH-CLD.
Methods
Study Design and Patients
This is a randomised, placebo-controlled, double-blind, 
parallel-group study conducted over a 12-month treat-
ment period at a single centre in Dundee, Scotland 
between April 2015 and July 2017. The trial was 
approved by the East of Scotland Research Ethics 
Committee (reference: 14/ES/1035) and was carried out 
in accordance with the Declaration of Helsinki. This 
study has been registered with the International 
Standard Randomized Controlled Trial Number register 
(ISRCTN11081180) and European Clinical Trials 
Database (EudraCT no: 2014–002305-38).
We recruited patients from the chest clinics at the local 
hospital, from local respiratory databases, from general 
practices covering two UK National Health Service boards 
(Tayside and Fife) via the Scottish Primary Care Research 
Network, and from the Scottish Health Research Register. 
Box 1 shows the study eligibility criteria. All patients 
provided written informed consent. All their usual medica-
tions were continued throughout the study. 
Box 1 Inclusion and Exclusion Criteria
Inclusion criteria
● Male or female participants aged 18 years or over
● Known diagnosis of chronic obstructive pulmonary disease or 
interstitial lung disease
● Stable lung disease medication for at least two weeks prior to 
consent
● Pulmonary acceleration time < 110 ms and/or right ventricular 
systolic pressure > 25 mm Hg and/or right ventricular free wall 
thickness ≥ 5.5 mm (on screening echocardiography)
Exclusion criteria
● Documented allergy or intolerance to allopurinol
● Active gout (i.e flare up < 2 years) or currently taking allopurinol
● Left ventricular ejection fraction < 45% on echocardiography
● Severe aortic stenosis on echocardiography
● Severe hepatic disease
● Chronic kidney disease class 3B or greater
● Patients taking azathioprine, 6-mercaptopurine, or theophylline
● Malignancy (receiving active treatment) or other life threatening 
diseases
● Any contraindication to MRI (claustrophobia, metal implants)
Randomisation and Masking
Eligible patients were randomly assigned by a validated 
computer-generated random allocation sequence to a study 
number. The patients were given the trial medication, 
which was either allopurinol or matched placebo, carrying 
their unique study number. At baseline visit, they would 
receive either allopurinol 100 mg/day or matched placebo 
orally for two weeks. If this was tolerated, the trial med-
ication was increased to 300mg of allopurinol or placebo 
for four weeks. The dosage was further increased after this 
four week period to the target dose of 600mg (given as 
300 mg twice daily) for the remaining duration of the trial. 
The intervention and placebo capsules and bottles looked 
identical and double blinding was maintained throughout. 
Patients, study investigators and outcome assessors were 
masked to group allocation. Unmasking was done only 
after the end of the trial.
Procedures
All recruited participants underwent screening echocardio-
graphy to check if they were eligible. PLSC undertook 
echocardiography with either Philips iE33 system (Philips, 
Netherlands) or Philips Epiq7 ultrasound system (Philips 
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Ultrasound, USA). If the measurements were difficult to 
obtain using standard acoustic windows, the oblique sub-
costal windows were used to assess the pulmonary accel-
eration time with pulse-wave Doppler.15 The estimated 
mean pulmonary arterial pressure (MPAP) was then calcu-
lated with Dabestani equation, and/or the right ventricular 
systolic pressure with the Bernoulli equation.16
All participants underwent spirometry, six-minute walk 
test (6MWT) and cardiac MRI scan at randomisation visit 
and these measures were repeated at final visit. Spirometry 
was performed using MicroLoop spirometer (Micro Medical, 
Rochester, UK) as per ATS/ERS guidelines and 6MWT was 
performed as per ATS guidelines.17,18 Patients were allowed 
to use their usual walking aids but participants on LTOT did 
their 6MWT off oxygen. Oxygen saturation during the 
6MWT was measured using portable pulse oximeter.
Quality of life (QOL) at baseline and final visits was 
assessed using the St George’s Respiratory Questionnaire 
(SGRQ) and the King’s Brief Interstitial Lung Disease 
(K-BILD) questionnaire. The 36-Item Short Form Survey 
(SF-36) was also used to assess general QOL measure.
Blood samples were taken at baseline and final visits 
for N-terminal prohormone of brain natriuretic peptide 
(NT-proBNP) and high-sensitive troponin I (hs-Trop I).
Cardiac MRI
Cardiac magnetic resonance imaging (CMRI) was per-
formed at baseline and at final visit only. The images were 
acquired on a 32 RF cardiac receiver channel, 3 Tesla MRI 
scanner (Prisma, Siemens, Erlangen, Germany) using dedi-
cated cardiac coils as previously described.19 The images 
were exported, and analysis performed offline by an inde-
pendent, blinded radiologist (JWM), with five years experi-
ence in CMRI, using CVI 42 (Circle Cardiovascular 
Imaging software, Calgary, Canada).
The epicardial and endocardial contours were drawn 
around the right ventricle at end systole and end diastole. 
Trabeculae were included in the mass measurement and 
excluded from the volume calculation. The septum was 
treated as belonging to the left ventricle and was excluded 
from the right ventricular mass (RVM). Ventricular mass 
and volumes were indexed to body surface area, which 
was calculated using the Mosteller formula.20
Outcomes
The primary outcome was the mean difference between the 
baseline and final right ventricular mass index after 12 months 
of allopurinol compared to placebo. Secondary outcomes 
included change in other cardiac MRI measurements, lung 
function (spirometry), exercise capacity (6MWT), quality of 
life measures (SGRQ, K-BILD, SF-36), and blood markers 
(NT-proBNP, hs-Trop I).
Statistical Analysis
Bradlow et al,21 advised that 34 patients are required to 
have 80% power at p < 0·05 to detect changes in the 
manually measured outcomes of RV mass of 10g. 
However, a 10g change in ventricular mass was over 
ambitious. 66 patients were required to achieve 80% 
power to detect a 5g change in RVM at a significance 
level of p < 0·05, based on previous studies investigating 
the allopurinol’s effect on left ventricular mass using 
CMRI.12–14 In order to allow for 10% drop-outs, 72 eligi-
ble patients were recruited.
The primary analysis was based on the intention-to- 
treat principle. The extent of missing data was examined 
and the reason for drop-out was ascertained. Multiple 
imputations have been used to impute missing values and 
where assumptions for missing at random data were met. 
Complete case analysis where missing patients are 
excluded was carried out as a secondary analysis.
The data for continuous outcome measures were 
assessed for normality of distribution prior to analysis. 
The descriptive statistics was reported in the form of 
mean ± standard deviation (SD) for normally distributed 
continuous variables, median and interquartile range (IQR) 
for non-normally distributed continuous variables, and 
percentages and denominators for categorical variables 
are tabulated at the baseline visit. The comparison between 
continuous variables is analysed using paired t-tests (to 
test within group differences), independent t-test (to test 
between group differences), or Mann–Whitney U-test (for 
non-normally distributed data) whilst categorical variables 
were analysed using Chi-squared test.
All statistical analyses were undertaken blinded using 
IBM SPSS Statistics v22·0 (IBM, United States). A two- 
sided p value < 0·05 was considered statistically significant.
Results
The flow of participants is depicted in the CONSORT 
diagram (Figure 1). A total of 72 participants were 
recruited for the study. One patient was randomised but 
excluded from analysis as he was unable to undergo base-
line CMRI due to claustrophobia. 36 received allopurinol 
and 35 received placebo. 63 (89%) participants completed 
the study per protocol and the average follow-up period 
Dovepress                                                                                                                                              Liu-Shiu-Cheong et al
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was 11·3 months for completers. The compliance from 
tablet counting was high at 96%. All the participants 
tolerated a daily dosage of 600 mg of allopurinol except 
1 participant who was left on 300 mg as he developed 
fatigue and lethargy while taking 600 mg.
The baseline characteristics were similar between the 
two groups (Table 1): mean age 71 years, estimated MPAP 
30 mm Hg, mean FEV1 60% predicted, resting oxygen 
saturation (SaO2) 96% and predominantly male (62%). 
66 (93%) participants had COPD and five (7%) had IPF. 
Five patients were on LTOT. There were eight study 
dropouts (allopurinol n = 5, placebo = 3): participant’s 
preference (n = 4), depression (n = 2), metastatic bladder 
cancer (n = 1) and death (n = 1). No patient receiving 
LTOT needed an increase in oxygen dose. One patient in 
the placebo who was already on ambulatory oxygen was 
prescribed LTOT during the trial period.
At baseline, RVM and RVMI were similar in both groups 
(Table 2). In the intention-to-treat analysis (Table 3), there 
was no significant difference between allopurinol group and 
placebo group in the change in RVM (allopurinol group 1.85 
± 1.56 g vs placebo group 0.97 ± 1.20 g; p = 0.66) and in the 
change in RVMI (allopurinol group 0.70 ± 0.75 g/m2 vs 
placebo group 0.50 ± 0.60 g/m2; p = 0.83). There was also 
no significant difference in the change in RVM and RVMI 
when per-protocol analysis was performed. In the post-hoc 
Figure 1 CONSORT diagram showing participant flow through the study.
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exploratory subgroup analysis according to severity of air-
flow limitation (Table 4), participants with more severe air-
flow limitation (GOLD 3 and 4) showed significant reduction 
in RVM (allopurinol group −6.16 ± 1.97 g vs placebo group 
0.75 ± 1.71 g; p = 0.02) and in RVMI (allopurinol group 
−3.13 ± 1.00 g/m2 vs placebo group 0.54 ± 0.85 g/m2; 
p = 0.02). (Figure 2)
For the other parameters measured on CMRI for both 
right and left ventricles, there were no significant changes 
in end-systolic volume (ESV), end-diastolic volume 
(EDV), ejection fraction (EF), stroke volume (SV) and 
their indexed values (Table 3). There were also no statis-
tically significant changes in any of the quality-of-life, 
6MWT and spirometric measurements (Table 5). There 
was no significant change in NT-proBNP and hs-Trop 
I levels over the study period (Table 6). There was 
a significant reduction in uric acid level by 59% with 
allopurinol treatment.
Another post-hoc exploratory subgroup analysis when 
stratifying by NT-proBNP level showed that the patients 
(n = 31) with higher NT-proBNP level (>489 pg/mL) had 
Table 1 Baseline Characteristics of Study Participants
Allopurinol 
(n = 36)
Placebo 
(n = 35)
p
Age (years) 70 (5) 71 (6) 0.45
Male sex (%) 22 (61) 22 (63)
Height (m) 1.65 (0.11) 1.68 (0.09) 0.29
Weight (kg) 80.2 (16.6) 82.7 (17.0) 0.54
BMI (kg/m2) 29 (5) 29 (5) 0.98
Heart rate (bpm) 79 (14) 78 (13) 0.99
Systolic BP (mm Hg) 138 (16) 140 (19) 0.67
Diastolic BP (mm Hg) 76 (9) 75 (14) 0.93
mMRC dyspnoea scale 2.8 (1.3) 2.7 (1.2) 0.14
WHO Functional class 2.3 (0.8) 2.4 (0.7) 0.48
Smoking status
● Current smoker
● Ex-/non-smoker
9 (25) 
27 (75)
8 (23) 
27 (77)
Pack-year history 46.9 (27.4) 50.3 (28.6) 0.61
Long-term oxygen 3 (8) 2 (6)
SaO2 (%) 96 (3) 96 (3) 0.67
PAT (ms) 94.9 (9.6) 97.1 (12.1) 0.38
COPD
● FEV1 (% predicted)
34 (94) 
60 (21)
32 (91) 
58 (20) 0.64
ILD 2 (6) 3 (9)
Notes: Data are mean (SD), n (%) or median (IQR): Independent samples t-test for 
normally-distributed continuous variables and Mann–Whitney U-test for non- 
parametric data. 
Abbreviations: BMI, body mass index; mMRC, modified medical research council; 
FEV1, forced expiratory volume in 1 sec; SaO2, blood oxygen saturation; PAT, 
pulmonary acceleration time; COPD, chronic obstructive pulmonary disease; 
FEV1, forced expiratory volume in 1 sec; ILD, interstitial lung disease.
Table 2 Baseline Cardiac MRI Measurements
Allopurinol 
(n = 36)
Placebo 
(n = 35)
p
RVM (g) 40.27 (1.62) 41.19 (2.06) 0.73
RVMI (g/m2) 21.02 (0.68) 20.88 (0.83) 0.90
RVESV (mL) 49.7 (2.9) 55.8 (3.6) 0.19
RVESVI (mL/m2) 26.1 (1.6) 28.3 (1.7) 0.33
RVEDV (mL) 118.6 (5.2) 129.1 (5.8) 0.17
RVEDVI (mL/m2) 62.2 (2.5) 65.5 (2.3) 0.34
RVSV (mL) 68.8 (3.3) 73.4 (3.8) 0.35
RVEF (%) 57.0 (2.0) 56.5 (1.7) 0.85
RA area (cm2) 20.8 (0.9) 21.9 (1.2) 0.45
LVM (g) 106.8 (4.8) 105.9 (4.9) 0.89
LVMI (g/m2) 55.5 (1.8) 53.7 (2.0) 0.52
LVSV (mL) 70.9 (3.4) 76.3 (3.3) 0.25
LVEF (%) 52.9 (1.9) 56.8 (1.5) 0.10
LA area (cm2) 21.1 (1.1) 22.8 (1.3) 0.35
VMI 0.39 (0.01) 0.39 (0.01) 0.69
Notes: Data are mean (SEM): Independent samples t-test for normally-distributed 
continuous variables and Mann–Whitney U-test for non-parametric data. 
Abbreviations: RVM, right ventricular mass; RVMI, right ventricular mass index; 
RVESV, right ventricular end-systolic volume; RVEDV, right ventricular end-diastolic 
volume; RVSV, right ventricular stroke volume; RVEF, right ventricular ejection 
fraction; RA area, right atrial area; LVM, left ventricular mass; LVMI, left ventricular 
mass index; LVSV, left ventricular stroke volume; LVEF, left ventricular ejection 
fraction; LA area, left atrial area; VMI, ventricular mass index.
Table 3 CMRI Changes After Allopurinol Treatment (Intention- 
to-Treat Analysis)
Allopurinol 
(n = 36)
Placebo 
(n = 35)
p
Right ventricle
Change in RVM (g) 1.85 (1.56) 0.97 (1.20) 0.66
Change in RVMI (g/m2) 0.70 (0.75) 0.50 (0.60) 0.83
Change in RVESV (mL) 4.8 (2.5) 3.8 (2.8) 0.79
Change in RVESVI (mL/m2) 1.9 (1.3) 1.7 (1.4) 0.92
Change in RVEDV (mL) 8.8 (4.2) 5.6 (4.2) 0.59
Change in RVEDVI (mL/m2) 4.0 (2.2) 3.1 (2.2) 0.75
Change in RVSV (mL) 3.0 (3.1) 1.6 (2.7) 0.73
Change in RVSVI (mL/m2) 1.4 (1.7) 1.1 (1.3) 0.88
Change in RVEF (%) 1.3 (2.4) 1.7 (1.7) 0.91
Change in RA area (cm2) −2.2 (1.5) −0.6 (1.5) 0.45
Left ventricle
Change in LVM (g) 0.8 (3.2) −1.9 (2.8) 0.52
Change in LVMI (g/m2) 0.1 (1.5) −1.1 (1.2) 0.53
Change in LVSV (mL) 5.8 (3.3) 0.4 (2.6) 0.20
Change in LVEF (%) 3.0 (2.0) 0.0 (1.3) 0.20
Change in LA area (cm2) 0.6 (0.1) −0.3 (0.8) 0.49
Note: Data are mean (SEM). 
Abbreviations: RV, right ventricular; LV, left ventricular; MI, mass index; ESV, end 
systolic volume; EDV, end diastolic volume; SV, stroke volume; EF, ejection fraction.
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a greater improvement in LVEF with allopurinol 5.12 ± 
2.36% vs placebo −1.62 ± 1.51% (p = 0.02). There was no 
significant difference in the change in RVM (allopurinol 
group 1.04 ± 1.33 g vs placebo −0.56 ± 4.42 g; p = 0.44) 
and in RVMI (allopurinol group 0.63 ± 0.72 g/m2 vs 
placebo group −0.05 ± 0.67 g/m2; p = 0.50) in this 
subgroup.
There was a total of 179 adverse events (AE) recorded 
with 80 (45%) in the allopurinol group and 99 (55%) in 
the placebo group. There were 7 serious adverse events 
(SAE) in the allopurinol group compared to 15 SAE in the 
placebo group.
Discussion
High dose allopurinol exhibited no overall effect on the 
RVM, as measured by cardiac MRI. This could be due to 
the heterogeneity of severity in chronic lung disease. 
Recent studies have demonstrated the wide range of phe-
notypes and heterogeneity of patients suffering from 
COPD.22 The overall effect of allopurinol could have 
Table 4 CMRI Changes for RV After Allopurinol Treatment in 
Subgroup GOLD 3 and 4
Allopurinol 
(n = 7)
Placebo 
(n = 13)
p
Change in RVM (g) −6.16 (1.97) 0.75 (1.71) 0.02
Change in RVMI (g/m2) −3.13 (1.00) 0.54 (0.85) 0.02
Change in RVESV (mL) −1.4 (6.6) 2.5 (5.8) 0.68
Change in RVESVI (mL/m2) −1.4 (4.1) 1.5 (3.0) 0.59
Change in RVEDV (mL) 4.9 (6.2) 4.7 (6.7) 0.98
Change in RVEDVI (mL/m2) 3.7 (3.4) 3.1 (3.6) 0.91
Change in RVSV (mL) 1.0 (9.3) 1.9 (2.8) 0.92
Change in RVSVI (mL/m2) 1.9 (5.8) 1.4 (1.6) 0.92
Change in RVEF (%) 2.0 (7.7) 0.4 (2.4) 0.81
Note: Data are mean (SEM). 
Abbreviations: RV, right ventricular; LV, left ventricular; MI, mass index; ESV, end 
systolic volume; EDV, end diastolic volume; SV, stroke volume; EF, ejection fraction.
Figure 2 Scatter plots of RVM and RVMI (mean and SEM) for overall population (allopurinol n=31, placebo n=32) and subgroup GOLD 3 and 4 (allopurinol n=7, placebo 
n=13). There were significant (p = 0·02) differences in RVM and RVMI in the subgroup of GOLD 3/4 patients.
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been different if we had considered only patients with 
specific phenotypes of the disease. As this was a proof of 
concept study, it was not possible to restrict to specific 
phenotypes as there were no previous studies that had 
already evaluated this.
The right ventricular mass of our study population was 
relatively not too high compared to studies in patients with 
idiopathic pulmonary arterial hypertension23,28 This is 
probably because pulmonary hypertension in COPD and 
ILD patients tends to be milder in severity compared to 
group 1 patients.1 One could say that because RVM was 
not high, then our population did not have pulmonary 
hypertension. However, there was evidence of pulmonary 
hypertension on CMRI as demonstrated by a higher ven-
tricular mass index (VMI) in our population compared to 
similar population of COPD and no PH studied by Johns 
et al.29 VMI correlates with invasive measurement of 
pulmonary artery pressure and has been shown to be 
a prognostic marker in pulmonary hypertension.30,31
Another possible explanation for the negative result for 
the primary outcome is that the study population consisted 
mostly of patients with COPD (93%) and a few patients 
suffering from ILD (7%). It was agreed at the time when 
the study was designed to include patients suffering from 
group 3 pulmonary hypertension. However, it is still not 
completely clear whether the pathophysiology underlying 
the development of PH and RVH is the same for all the 
chronic lung diseases.
The heterogeneous study population may have 
masked a possible effect of allopurinol. This is supported 
by the finding that there was a statistically significant 
difference in the allopurinol group amounting to a mean 
difference of 6.92g in a subgroup of patients with more 
severe airflow obstruction corresponding to GOLD 
groups 3 and 4. This in turn suggests that the more 
severe the degree of airflow limitation, the more likely 
allopurinol may reduce right ventricular mass. 
A potential explanation is that such patients are more 
likely to be more hypoxic on exertion (despite having 
satisfactory resting oxygen saturation), causing increas-
ing oxidative stress, leading to cardiac hypertrophy and 
increased pulmonary arterial pressures on exercise. The 
observed trend towards a reduction in RVESV conferred 
by allopurinol suggests that offloading the RV may have 
been the mechanism for the RVH regression, further 
Table 5 Mean Change in Quality-of-Life Scores, Spirometry and 
Six-Minute Walk Measurements at 52 Weeks Compared to 
Baseline (Intention-to-Treat Analysis)
Allopurinol 
(n = 36)
Placebo 
(n = 35)
p
SGRQ
Total score −0·89 (1·72) −1·30 (1·95) 0·88
Symptom score −2·82 (2·96) 1·55 (3·67) 0·35
Activity score 1·93 (2·31) −1·31 (2·39) 0·84
Impact score −1·70 (2·31) −2·37 (2·41) 0·84
SF-36
Physical functioning −1·06 (3·09) 2·92 (2·42) 0·31
Physical role limitations 1·66 (5·74) 8·15 (6·45) 0·45
Emotional role limitations −5·77 (6·48) 1·45 (8·47) 0·50
Energy or fatigue −0·81 (2·64) 4·53 (3·81) 0·25
Emotional well-being 4·65 (2·85) 0·29 (3·07) 0·30
Social functioning −2·43 (3·63) −1·62 (3·98) 0·88
Pain −4·08 (3·51) 1·13 (4·67) 0·37
General health 0·12 (2·73) −0·02 (3·33) 0·97
Health change 5·56 (4·02) 6·96 (5·29) 0·83
Spirometry
FEV1 0·02 (0·03) −0·01 (0·03) 0·42
FEV1% 1·55 (1·31) 0·16 (1·08) 0·41
FVC 0·02 (0·05) 0·02 (0·06) 0·98
FVC% 0·97 (1·41) 1·00 (1·78) 0·99
FEV1/FVC 0·97 (1·41) 1·00 (1·78) 0·74
6MWT
Distance 8·8 (10·0) −10·0 (12·5) 0·24
Pre-test O2 −0·4 (0·3) −0·8 (0·4) 0·51
Post-test O2 −1·3 (0·9) −0·5 (0·8) 0·52
Note: Data are mean (SEM). 
Abbreviations: SGRQ, St George Respiratory Questionnaire; SF-36, Short Form 
(36); FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; 6MWT, six- 
minute walk test.
Table 6 Mean Change in Blood Markers at 52 Weeks Compared 
to Baseline (Intention-to-Treat Analysis)
Allopurinol 
(n = 36)
Placebo 
(n = 35)
p
Baseline NT-proBNP (pg/ 
mL)
916·81 
(248·62)
949·31 (275·13) 0·93
Final NT-proBNP (pg/mL) 829·18 
(233·20)
1238·68 
(376·36)
0·35
Change in NT-proBNP (pg/ 
mL)
−87·6 (127·2) 289·4 (213·3) 0·13
Baseline hs-Trop I (pg/mL) 3·22 (0·55) 3·59 (0·73) 0·69
Final hs-Trop I (pg/mL) 3·03 (0·41) 3·77 (0·79) 0·40
Change in hs-Trop I (pg/mL) −0·20 (0·48) 0·18 (0·37) 0·53
Baseline Urate (μmol/l) 350·06 (13·54) 342·94 (15·37) 0·73
Final Urate (μmol/l) 144·12 (9·12) 338·34 (15·59) < 0·001
Change in Urate (μmol/l) −205·9 (14·9) −4·6 (8·5) < 0·001
Note: Data are mean (SEM). 
Abbreviations: NT-proNBP, N-terminal prohormone brain natriuretic peptide; 
Hs-Trop I, high sensitive troponin I.
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supported by similar observations of left ventricular 
mass reduction and improved systolic function reported 
by Rekhraj et al study13 of left ventricular hypertrophy.
The overall negative results in our study may be 
because the current study population had too mild chronic 
lung disease. The positive signal that was found in our 
subgroup analysis suggests that the study needs to be 
repeated in patients with more severe chronic lung disease 
to ascertain the benefits of allopurinol in that population 
who have the greatest need of new treatments.
It is difficult to compare the results of the current study 
with other randomised clinical trials (RCT) as to date there 
is no other RCT looking at the cardiac mass, volume and 
function in patients with group 3 pulmonary hypertension. 
The closest studies that could be compared with are long-
itudinal ones in patients with group 1 pulmonary hyperten-
sion who received drug therapies already licensed to treat 
pulmonary hypertension in this group. The results from 
these studies were mixed: the studies by Michelakis et al,26 
van Wolferen et al,23 and van de Veerdonk,28 and the 
SERAPH study24 have reported a reduction in RVM 
from baseline while the study by Roeleveld et al,27 and 
the EURO-MR study25 reported no change in RVM.
Two recent studies32,33 have reported improvements in 
ventricular volumes and function in COPD population 
following treatment with inhaled therapies. However, 
these studies were looking at a particular phenotype of 
COPD, namely those with lung hyperinflation which 
induces cardiac under-filling. Lung hyperinflation or gas 
trapping was not specifically evaluated in the current 
study.
We have also found that allopurinol improved left 
ventricular ejection fraction in a subgroup of patients 
who had higher NT-proBNP level. A possible mechanism 
for this finding could be the ability of allopurinol to 
improve cardiac energetics by improving relative and 
absolute concentrations of myocardial high-energy phos-
phates and ATP flux through creatinine kinase, which has 
been observed in left heart failure.34
One of the limitations of this study is that right heart 
catheterisation (RHC), which is the gold standard for 
assessing pulmonary haemodynamics, was not per-
formed. RHC is invasive and it would introduce unne-
cessary risk and reduce the number of patients willing to 
be recruited, hence potentially making recruits atypical. 
It is also not routine practice in patients with COPD and 
suspected borderline or mild pulmonary hypertension. 
Pulmonary acceleration time is a good alternative and 
non-invasive echo measurement that has a correlation 
coefficient of r = 0.88 with pulmonary pressures.35
Another limitation is the lack of data on transfer factor 
of the lung for carbon monoxide (TLCO). Reduction in 
TLCO is common in COPD, due to emphysema, while 
pulmonary hypertension causes a further reduction in the 
TLCO which would have helped to further characterise the 
study population. However, as it was not expected that 
allopurinol would have any beneficial effect on transfer 
factor and to limit testing burden on the trial participants, 
it was not included in the current study.
Conclusion
In conclusion, there was no overall effect of allopurinol on 
right ventricular mass in patients with pulmonary hyper-
tension associated with chronic lung disease. There was 
also no overall effect of allopurinol on LV and RV mea-
surements, quality of life, spirometry, six-minute walk test 
and blood markers.
There was a potential benefit of allopurinol in COPD 
patients with more severe airflow limitation (FEV1 < 50% 
predicted) and in patients with higher NT-proBNP levels. 
Further studies are warranted to assess the longer-term 
impact of allopurinol in this population.
Abbreviations
6MWT, six minute walk test; AE, adverse event; CMRI, 
cardiac magnetic resonance imaging; COPD, chronic 
obstructive pulmonary disease; EDV, end diastolic 
volume; EF, ejection fraction; ESV, end systolic volume; 
FEV1, forced expiratory volume in 1 second; Hs-Trop I, 
high-sensitive troponin I; ILD, interstitial lung disease; 
IPF, idiopathic pulmonary fibrosis; K-BILD, King’s brief 
interstitial lung disease; LTOT, long term oxygen therapy; 
LV, left ventricle; MPAP, mean pulmonary arterial pres-
sure; NT-proBNP, N-terminal prohormone of brain 
natriuretic peptide; OS, oxidative stress; PH, pulmonary 
hypertension; PH-CLD, pulmonary hypertension asso-
ciated with chronic lung disease; QOL, quality of life; 
RCT, randomised controlled trial; RHC, right heart cathe-
terisation; RV, right ventricle; RVH, right ventricular 
hypertrophy; RVM, right ventricular mass; RVMI, right 
ventricular mass index; SAE, serious adverse event; SF- 
36, 36-Item Short Form Survey; SGRQ, St George’s 
Respiratory Questionnaire; SpO2, oxygen saturation; SV, 
stroke volume; TLCO, transfer factor of the lung for 
carbon monoxide; UA, uric acid; VMI; ventricular mass 
index.
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